Pembrolizumab-Induced Acute Skin Reaction: A Case Report and Review of Literature

The development of immune checkpoint inhibitors is considered to be one of the most important advances in cancer treatment. Pembrolizumab is an immune checkpoint inhibitor against programmed death-ligand 1 (PD-L1) receptor that has demonstrated antineoplastic activity against various malignancies in...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Mathew, Wazir, Ali, Poudel, Aarati
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216225/
https://www.ncbi.nlm.nih.gov/pubmed/35754442
http://dx.doi.org/10.7759/cureus.26143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216225/
https://www.ncbi.nlm.nih.gov/pubmed/35754442
http://dx.doi.org/10.7759/cureus.26143

Ejemplares similares